2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 753

Progress Report On Development of Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies
Abstract Number: 824

Progressive Improvements in Cortical Mass and Thickness throughout the Hip Were Observed with Denosumab Treatment in the Freedom Trial
Abstract Number: 2660

Progressive Radiographic Joint Damage in Established Rheumatoid Arthritis: Common and Strongly Associated with Seropositivity
Abstract Number: 2462

Projecting the Direct Cost Burden of Osteoarthritis in Canada Using a Population-Based Microsimulation Model From [2010-2031]
Abstract Number: 1078

Prolactin Is Increased in Responders to Anti-TNFá Treatment and the Role of the Prolactin Receptor in Rheumatoid Arthritis
Abstract Number: 670

Prolidase Deficiency Induces Antibodies to Sm, Ro60 and Double Stranded DNA
Abstract Number: 1695

Prolonged Exposure to Subcutaneous and Intravenous Abatacept in Patients with Rheumatoid Arthritis Does Not Affect Rates of Infection, Malignancy and Autoimmune Events: Results From Pooled Clinical Trial Data
Abstract Number: 621

Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide
Abstract Number: 143

Proposed Gout Treatment Guidelines and Meeting Serum Urate and Flare Goals
Abstract Number: 1507

Propylthiouracil Reduces Fibrosis in Chronic Oxidant Stress Mouse Model of Scleroderma
Abstract Number: 2110

Prospective Assessement of Bone Texture Parameters At the Hand in Rheumatoid Arthritis
Abstract Number: 351

Prospective Follow-up of Tocilizumab Treatment in 764 Patients with Refractory Rheumatoid Arthritis: Tolerance and Efficacy Data From the French Registry Regate (REGistry –RoAcTEmra)
Abstract Number: 1199

Proteases Produced by Porphyromonas Gingivalis Can Cleave and Citrullinate Substrates Found in the Joint and Oral Mucosa: Implications for Autoimmunity in Rheumatoid Arthritis
Abstract Number: 2492

Protective and Pathogenic Effects of the IL-23 Family of Cytokines in Spondyloarthropathy in SKG Mice
Abstract Number: 22

Protective Properties of Conditioned Media From Adipose Stem Cells On Osteoarthritic Chondrocytes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].